Tau immunotherapies: Lessons learned, current status and future considerations
Open accessAbstract
The majority of clinical trials targeting the tau protein in Alzheimer's disease and other tauopathies are tau immunotherapies. Because tau pathology correlates better with the degree of dementia than amyloid-β lesions, targeting tau is likely to be more effective in improving cognition than clearing amyloid-β in Alzheimer's disease. However, the development of tau therapies is in many ways more complex than for amyloid-β therapies as briefly outlined in this review. Most of the trials are on humanized antibodies, which may have very different properties than the original mouse antibodies. The impact of these differences are to a large extent unknown, can be difficult to decipher, and may not always be properly considered. Furthermore, the ideal antibody properties for efficacy are not well established and can depend on several factors. However, considering the varied approaches in clinical trials, there is a general optimism that at least some of these trials may provide functional benefits to patients suffering of various tauopathies. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In clinical trials, immunotherapies make up the majority of tau-targeting treatments.
“In clinical trials, immunotherapies make up the majority of tau-targeting treatments.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [97]
Various forms of P-tau provide non-invasive cost-effective prediction as biomarkers.
“For example, various forms of P-tau provide non-invasive cost-effective prediction as biomarkers [50].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works
Cryo-EM structures of tau filaments from Alzheimer’s disease
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061 · see citing works
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · see citing works
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803 · see citing works
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133 · see citing works
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 7× · see citing works
“Tau antibodies have been shown to target tau intracellularly and extracellularly and thus hold great therapeutic promise across various neuropathological conditions where aberrant tau is present; however, the majority of tau and the most likely to be clinically beneficial target is that of intracellular tau (Congdon a…”
BackgroundMethodInfluentialSelf-citationStructures of filaments from Pick’s disease reveal a novel tau protein fold
Falcon, B., Zhang, W., Murzin, A. G., Murshudov, G. N., Garringer, H. J., Vidal, R., Crowther, R. A., Ghetti, B. F., Scheres, S. H. W., & Goedert, M. (2018) · Nature · doi:10.1038/s41586-018-0454-y · Cited by 837 · see citing works
The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans
Holth, J. K., Fritschi, S. K., Wang, C., Pedersen, N. P., Cirrito, J. R., Mahan, T. E., Finn, M. B., Manis, M., Geerling, J. C., Fuller, P. M., et al. (2019) · Science · doi:10.1126/science.aav2546 · Cited by 813 · see citing works
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809 · see citing works
Tau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806 · see citing works
Post-translational modifications of tau protein: Implications for Alzheimer's disease
Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 645 · see citing works
Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles
Guo, J. L., & Lee, V. M.-Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209296 · Cited by 636 · see citing works
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · see citing works
Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574 · see citing works
Neuronal activity regulates extracellular tau in vivo
Yamada, K., Holth, J. K., Liao, F., Stewart, F. R., Mahan, T. E., Jiang, H., Cirrito, J. R., Patel, T. K., Hochgräfe, K., Mandelkow, E., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131685 · Cited by 574 · see citing works
Mouse and human FcR effector functions
Bruhns, P., & Jönsson, F. (2015) · Immunological Reviews · doi:10.1111/imr.12350 · Cited by 573 · see citing works
Trans-cellular Propagation of Tau Aggregation by Fibrillar Species
Kfoury, N., Holmes, B. B., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.346072 · Cited by 552 · see citing works
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works
Self-citationThe propagation of prion-like protein inclusions in neurodegenerative diseases
Goedert, M., Clavaguera, F., & Tolnay, M. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.04.003 · Cited by 451 · see citing works
Kaufman, S. K., Sanders, D. W., Thomas, T. L., Ruchinskas, A. J., Vaquer-Alicea, J., Sharma, A. M., Miller, T. M., & Diamond, M. I. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.055 · Cited by 450 · see citing works
Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy
Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.-H., Yao, Y., Lin, Y.-M., Driver, J. A., Sun, Y., et al. (2015) · Nature · doi:10.1038/nature14658 · Cited by 445 · see citing works
Post-translational modifications of tau protein in Alzheimer’s disease
Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437 · see citing works
Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411 · see citing works
Glial contributions to neurodegeneration in tauopathies
Leyns, C. E. G., & Holtzman, D. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0192-x · Cited by 409 · see citing works
Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains
Arakhamia, T., Lee, C. E., Carlomagno, Y., Kumar, M., Duong, D. M., Wesseling, H., Kundinger, S. R., Wang, K., Williams, D., Deture, M. A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.027 · Cited by 400 · see citing works
What is the evidence that tau pathology spreads through prion-like propagation?
Mudher, A., Colin, M., Dujardin, S., Medina, M., Dewachter, I., Alavi Naini, S. M., Mandelkow, E.-M., Mandelkow, E., Buée, L., Goedert, M., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0488-7 · Cited by 384 · see citing works
Takeda, S., Wegmann, S., Cho, H., DeVos, S. L., Commins, C., Roe, A. D., Nicholls, S. B., Carlson, G. A., Pitstick, R., Nobuhara, C. K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9490 · Cited by 371 · see citing works
Alzheimer’s pathogenesis: is there neuron-to-neuron propagation?
Braak, H., & Tredici, K. D. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0825-z · Cited by 359 · see citing works
Yamada, K., Cirrito, J. R., Stewart, F. R., Jiang, H., Finn, M. B., Holmes, B. B., Binder, L. I., Mandelkow, E.-M., Diamond, M. I., Lee, V. M.-Y., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2569-11.2011 · Cited by 351 · see citing works
Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models
Chai, X., Wu, S., Murray, T. K., Kinley, R. D., Cella, C. V., Sims, H., Buckner, N., Hanmer, J. M., Davies, P., O’Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 346 · see citing works
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β<i>In Vivo</i>by Immunotherapy
Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323 · see citing works
Prion propagation and toxicity in vivo occur in two distinct mechanistic phases
Sandberg, M. K., Al-Doujaily, H., Sharps, B., Clarke, A. R., & Collinge, J. (2011) · Nature · doi:10.1038/nature09768 · Cited by 318 · see citing works
The molecular dissection of Fc gamma receptor mediated phagocytosis
Indik, Z. K., Park, J., HUNTER, S. E., & Schreiber, A. (1995) · Blood · doi:10.1182/blood.v86.12.4389.bloodjournal86124389 · Cited by 313 · see citing works
Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · see citing works
Self-citationNovák, P., Schmidt, R., Kontseková, E., Žilka, N., Kováčech, B., Škrabana, R., Kazmerova, Z., Katina, S., Fialová, Ľ., Prčina, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 306 · see citing works
A walk through tau therapeutic strategies
Jadhav, S., Ávila, J., Schöll, M., Kovács, G. G., Kövari, E., Škrabana, R., Evans, L., Kontseková, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 286 · see citing works
Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · see citing works
Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model
Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272 · see citing works
Self-citationPizzo, M. E., Wolak, D. J., Kumar, N. N., Brunette, E., Brunnquell, C. L., Hannocks, M., Abbott, N. J., Meyerand, M. E., Sorokin, L., Stanimirovic, D. B., et al. (2018) · The Journal of Physiology · doi:10.1113/jp275105 · Cited by 272 · see citing works
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259 · see citing works
Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works
Tau immunotherapy for Alzheimer's disease
Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works
Self-citationLuo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., & Paul, S. M. (2015) · Scientific Reports · doi:10.1038/srep11161 · Cited by 241 · see citing works
Human secreted tau increases amyloid-beta production
Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230 · see citing works
Mechanisms of Protein Seeding in Neurodegenerative Diseases
Walker, L. C., Diamond, M. I., Duff, K. E., & Hyman, B. T. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1453 · Cited by 226 · see citing works
Constitutive secretion of tau protein by an unconventional mechanism
Chai, X., Dage, J. L., & Citron, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.021 · Cited by 224 · see citing works
Goedert, M., & Spillantini, M. G. (2017) · Molecular Brain · doi:10.1186/s13041-017-0298-7 · Cited by 213 · see citing works
Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/-Knock-Out Mice
Das, P., HOWARD, V. G., Loosbrock, N., Dickson, D. W., Murphy, M. P., & Golde, T. E. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-24-08532.2003 · Cited by 212 · see citing works
Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209 · see citing works
Collin, L., Bohrmann, B., Göpfert, U., Oroszlan‐Szovik, K., Ozmen, L., & Grüninger, F. (2014) · Brain · doi:10.1093/brain/awu213 · Cited by 203 · see citing works
Li, T., Bourgeois, J., Celli, S., Glacial, F., Sourd, A. L., Mécheri, S., Weksler, B. B., Romero, I. A., Couraud, P., Rougeon, F., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-201384 · Cited by 202 · see citing works
Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation
McEwan, W. A., Falcon, B., Vaysburd, M., Clift, D., Oblak, A. L., Ghetti, B., Goedert, M., & James, L. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607215114 · Cited by 201 · see citing works
Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195 · see citing works
Self-citationZommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193 · see citing works
Nisbet, R. M., Van der Jeugd, A., Leinenga, G., Evans, H. T., Janowicz, P. W., & Götz, J. (2017) · Brain · doi:10.1093/brain/awx052 · Cited by 187 · see citing works
From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
Colin, M., Dujardin, S., Schraen-Maschke, S., Meno-Tetang, G., Duyckaerts, C., Courade, J.-P., & Buée, L. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02087-9 · Cited by 187 · see citing works
Tau passive immunization inhibits not only tau but also Aβ pathology
Dai, C., Tung, Y. C., Liu, F., Gong, C., & Iqbal, K. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0227-5 · Cited by 186 · see citing works
Anti‐tau antibody reduces insoluble tau and decreases brain atrophy
Yanamandra, K., Jiang, H., Mahan, T. E., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.176 · Cited by 185 · see citing works
Castillo‐Carranza, D. L., Gerson, J. E., Sengupta, U., Guerrero‐Munoz, M. J., Lasagna‐Reeves, C. A., & Kayed, R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132477 · Cited by 180 · see citing works
Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody
Albert, M., Mairet‐Coello, G., Danis, C., Lieger, S., Caillierez, R., Carrier, S., Skrobala, E., Landrieu, I., Michel, A., Schmitt, M., et al. (2019) · Brain · doi:10.1093/brain/awz100 · Cited by 177 · see citing works
Magnoni, S., Esparza, T. J., Conte, V., Carbonara, M., Carrabba, G. G., Holtzman, D. M., Zipfel, G. J., Stocchetti, N., & Brody, D. L. (2011) · Brain · doi:10.1093/brain/awr286 · Cited by 170 · see citing works
Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1948-2 · Cited by 168 · see citing works
Gu, J., Congdon, E. E., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494922 · Cited by 163 · see citing works
Self-citationNew roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease
Fuller, J. P., Stavenhagen, J. B., & Teeling, J. L. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00235 · Cited by 154 · see citing works
Bi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153 · see citing works
Albayram, Ö., Kondo, A., Mannix, R., Smith, C., Tsai, C.-Y., Li, C., Herbert, M. K., Qiu, J., Monuteaux, M. C., Driver, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01068-4 · Cited by 152 · see citing works
Prion-like Mechanisms in the Pathogenesis of Tauopathies and Synucleinopathies
Goedert, M., Falcon, B., Clavaguera, F., & Tolnay, M. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0495-z · Cited by 145 · see citing works
Therapy and clinical trials in frontotemporal dementia: past, present, and future
Tsai, R. M., & Boxer, A. L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13640 · Cited by 145 · see citing works
Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity
d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062402 · Cited by 144 · see citing works
Sankaranarayanan, S., Barten, D. M., Vana, L., Devidze, N., Yang, L., Cadelina, G. W., Hoque, N., DeCarr, L. B., Keenan, S., Lin, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125614 · Cited by 143 · see citing works
Barthélemy, N. R., Gabelle, A., Hirtz, C., Fenaille, F., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Junot, C., Becher, F., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150962 · Cited by 139 · see citing works
Formation and Propagation of Tau Oligomeric Seeds
Gerson, J. E., & Kayed, R. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00093 · Cited by 137 · see citing works
Li, T., Vandesquille, M., Koukouli, F., Dudeffant, C., Youssef, I., Lenormand, P., Ganneau, C., Maskos, U., Czech, C., Grueninger, F., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.019 · Cited by 133 · see citing works
Courade, J., Angers, R. C., Mairet‐Coello, G., Pacico, N., Tyson, K. L., Lightwood, D. J., Munro, R., McMillan, D., Griffin, R., BAKER, T. S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1911-2 · Cited by 131 · see citing works
Lee, S.-H., Le Pichon, C. E., Adolfsson, O., Gafner, V., Pihlgren, M., Lin, H., Solanoy, H., Brendza, R., Ngu, H., Foreman, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.099 · Cited by 125 · see citing works
Nobuhara, C. K., DeVos, S. L., Commins, C., Wegmann, S., Moore, B. D., Roe, A. D., Costantino, I., Frosch, M. P., Pitstick, R., Carlson, G. A., et al. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.01.022 · Cited by 120 · see citing works
Boxer, A., Qureshi, I., Ahlijanian, M., Grundman, M., Golbe, L., Litvan, I., Honig, L. S., Tuite, P., McFarland, N. R., O'Suilleabhain, P., et al. (2019) · Lancet Neurology · doi:10.1016/s1474-4422(19)30139-5 · Cited by 115 · see citing works
Distinct Therapeutic Mechanisms of Tau Antibodies
Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111 · see citing works
Different tau species lead to heterogeneous tau pathology propagation and misfolding
Dujardin, S., Bégard, S., Caillierez, R., Lachaud, C., Carrier, S., Lieger, S., Gonzalez, J. A., Deramecourt, V., Déglon, N., Maurage, C.-A., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0637-7 · Cited by 109 · see citing works
Advances and considerations in AD tau-targeted immunotherapy
Bittar, A., Bhatt, N. N., & Kayed, R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 105 · see citing works
Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy
Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2029 · Cited by 100 · see citing works
Dai, C.-L., Hu, W., Tung, Y. C., Liu, F., Gong, C.-X., & Iqbal, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0341-7 · Cited by 99 · see citing works
Characterization of tau oligomeric seeds in progressive supranuclear palsy
Gerson, J. E., Sengupta, U., Lasagna‐Reeves, C. A., Guerrero‐Munoz, M. J., Troncoso, J. C., & Kayed, R. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-73 · Cited by 95 · see citing works
Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I
Andoh, T., & Kuraishi, Y. (2003) · The FASEB Journal · doi:10.1096/fj.02-1169fje · Cited by 94 · see citing works
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders
Messer, A. C., & Butler, D. C. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104619 · Cited by 91 · see citing works
Dai, C., Chen, X., Kazim, S. F., Liu, F., Gong, C., Grundke, I., & Iqbal, K. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1315-y · Cited by 90 · see citing works
A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
Qureshi, I., Tirucherai, G., Ahlijanian, M. K., Kolaitis, G., Bechtold, C. M., & Grundman, M. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.007 · Cited by 90 · see citing works
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Novak, P., Kontsekova, E., Zilka, N., & Novak, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00798 · Cited by 87 · see citing works
Extracellular Tau and Its Potential Role in the Propagation of Tau Pathology
Yamada, K. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00667 · Cited by 84 · see citing works
Hickman, D. T., López-Deber, M. P., Ndao, D. M., Silva, A. B., Nand, D., Pihlgren, M., Giriens, V., Madani, R., St-Pierre, A., Karastaneva, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186338 · Cited by 83 · see citing works
Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic mice
Ittner, A., Bertz, J., Suh, L. S., Stevens, C. H., Götz, J., & Ittner, L. M. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12821 · Cited by 81 · see citing works
The Neurotoxic Role of Extracellular Tau Protein
Sebastián‐Serrano, Á., de Diego-García, L., & Dı́az-Hernández, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040998 · Cited by 81 · see citing works
Evidence for neuronal expression of functional Fc (ε and γ) receptors
van der Kleij, H. P. M., Charles, N., Karimi, K., Mao, Y., Foster, J. A., Janssen, L. J., Yang, P. C., Kunze, W., Rivera, J., & Bienenstock, J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.054 · Cited by 78 · see citing works
Tau oligomers in cerebrospinal fluid in Alzheimer's disease
Sengupta, U., Portelius, E., Hansson, O., Farmer, K., Castillo‐Carranza, D., Woltjer, R., Zetterberg, H., Galasko, D., Blennow, K., & Kayed, R. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.382 · Cited by 77 · see citing works
Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76 · see citing works
Self-citationPassive immunotherapy of tauopathy targeting pSer413‐tau: a pilot study in mice
Umeda, T., Eguchi, H., Kunori, Y., Matsumoto, Y., Taniguchi, T., Mori, H., & Tomiyama, T. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.171 · Cited by 73 · see citing works
Krishnamurthy, P., Deng, Y., & Sigurdsson, E. M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00059 · Cited by 71 · see citing works
Self-citationSingle-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases
Bélanger, K., Iqbal, U. H., Tanha, J., MacKenzie, R., Moreno, M., & Stanimirovic, D. B. (2019) · Antibodies · doi:10.3390/antib8020027 · Cited by 69 · see citing works
Liu, W., Zhao, L., Blackman, B. A., Parmar, M. S., Wong, M. Y., Woo, T., Yu, F., Chiuchiolo, M. J., Sondhi, D., Kaminsky, S. M., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2016-16.2016 · Cited by 68 · see citing works
Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls
Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-189010 · Cited by 67 · see citing works
Self-citationCongdon, E. E., Lin, Y., Rajamohamedsait, H. B., Shamir, D. B., Krishnaswamy, S., Rajamohamedsait, W. J., Rasool, S., González‐Calle, V., Levenga, J., Gu, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0126-z · Cited by 63 · see citing works
Self-citationIntracellular and Extracellular Roles for Tau in Neurodegenerative Disease
Hanger, D. P., Lau, D. H. W., Phillips, E. C., Bondulich, M. K., Guo, T., Woodward, B. W., Pooler, A. M., & Noble, W. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132054 · Cited by 62 · see citing works
Antibody-DerivedIn VivoImaging of Tau Pathology
Krishnaswamy, S., Lin, Y., Rajamohamedsait, W. J., Rajamohamedsait, H. B., Krishnamurthy, P., & Sigurdsson, E. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2755-14.2014 · Cited by 62 · see citing works
Self-citationp-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice
Walls, K. C., Ager, R. R., Vasilevko, V., Cheng, D., Medeiros, R., & LaFerla, F. M. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.05.047 · Cited by 58 · see citing works
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy
Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57 · see citing works
Pain, C., Dumont, J., & Dumoulin, M. (2015) · Biochimie · doi:10.1016/j.biochi.2015.01.012 · Cited by 56 · see citing works
Sigurdsson, E. M. (2016) · Neurodegenerative Diseases · doi:10.1159/000440842 · Cited by 56 · see citing works
Self-citationMagnoni, S., Donald, C. L. M., Esparza, T. J., Conte, V., Sorrell, J., Macrì, M., Bertani, G., Biffi, R., Costa, A., Sammons, B., et al. (2015) · Brain · doi:10.1093/brain/awv152 · Cited by 55 · see citing works
Congdon, E. E., Chukwu, J. E., Shamir, D. B., Deng, J., Ujla, D., Sait, H. B. R., Neubert, T. A., Kong, X., & Sigurdsson, E. M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.033 · Cited by 55 · see citing works
Self-citationVitale, F., Giliberto, L., Ruiz, S., Steslow, K., Marambaud, P., & d’Abramo, C. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0585-2 · Cited by 54 · see citing works
Agadjanyan, M. G., Zagorski, K., Petrushina, I., Davtyan, H., Kazarian, K., Antonenko, M., Davis, J. L., Bon, C., Blurton-Jones, M. M., Cribbs, D. H., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0172-1 · Cited by 53 · see citing works
Highly specific and selective anti‐pS396‐tau antibody C10.2 targets seeding‐competent tau
Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. C. A., Egebjerg, J., Falsig, J., Helboe, L., Jul, P., Kartberg, F., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.005 · Cited by 51 · see citing works
Self-citationN-terminal Truncation of Microtubule Associated Protein Tau Dysregulates its Cellular Localization
Paholikova, K., Šalingová, B., Opattová, A., Škrabana, R., Majerová, P., Žilka, N., Kováčech, B., Žilková, M., Baráth, P., & Novák, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140996 · Cited by 50 · see citing works
Schroeder, S. K., Joly‐Amado, A., Gordon, M. N., & Morgan, D. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9637-6 · Cited by 49 · see citing works
Rajamohamedsait, H., Rasool, S., Rajamohamedsait, W., Lin, Y., & Sigurdsson, E. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-17313-1 · Cited by 49 · see citing works
Self-citationPassive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies
d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135774 · Cited by 48 · see citing works
Potential candidate camelid antibodies for the treatment of protein-misfolding diseases
David, M. A., Jones, D. R., & Tayebi, M. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.05.001 · Cited by 46 · see citing works
[O2–14–05]: PRECLINICAL CHARACTERIZATION OF AN ANTIBODY [LY3303560] TARGETING AGGREGATED TAU
Alam, R., Driver, D. A., Wu, S., Lozano, E., Key, S., Hole, J. T., Hayashi, M. L., & Lu, J. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.227 · Cited by 45 · see citing works
A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor
Han, P., Serrano, G. E., Beach, T. G., Caselli, R. J., Yin, J., Zhuang, N., & Shi, J. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw105 · Cited by 44 · see citing works
Infectivity of amyloid diseases
Sigurdsson, E. M., Wisniewski, T., & Frangione, B. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02403-6 · Cited by 43 · see citing works
Self-citationFernández‐Vizarra, P., López‐Franco, Ó., Mallavia, B., Higuera‐Matas, A., López-Parra, V., Ortiz-Muñoz, G., Ambrosio, E., Egido, J., Almeida, O. F. X., & Gómez‐Guerrero, C. (2012) · Brain · doi:10.1093/brain/aws195 · Cited by 42 · see citing works
Emerging Diagnostic and Therapeutic Strategies for Tauopathies
Coughlin, D. G., & Irwin, D. J. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0779-1 · Cited by 39 · see citing works
Dupré, E., Danis, C., Arrial, A., Hanoulle, X., Homa, M., Cantrelle, F., Merzougui, H., Colin, M., Rain, J., Buée, L., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00217 · Cited by 35 · see citing works
Shamir, D. B., Rosenqvist, N., Rasool, S., Pedersen, J. T., & Sigurdsson, E. M. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.013 · Cited by 33 · see citing works
Self-citationDavtyan, H., Chen, W. W., Zagorski, K., Davis, J., Petrushina, I., Kazarian, K., Cribbs, D. H., Agadjanyan, M. G., Blurton-Jones, M., & Ghochikyan, A. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.020 · Cited by 30 · see citing works
Chukwu, J. E., Pedersen, J. T., Pedersen, L. Ø., Volbracht, C., Sigurdsson, E. M., & Kong, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-24276-4 · Cited by 30 · see citing works
Self-citationDynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging
Wu, Q., Lin, Y., Gu, J., & Sigurdsson, E. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.041 · Cited by 29 · see citing works
Self-citationTreatment with a non-toxic, self-replicating anti-prion delays or prevents prion disease in vivo
Díaz‐Espinoza, R., Morales, R., Concha‐Marambio, L., Moreno‐González, I., Moda, F., & Soto, C. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.84 · Cited by 28 · see citing works
Spencer, B. J., Brüschweiler, S., Sealey‐Cardona, M., Rockenstein, E. M., Adame, A., Florio, J. B., Mante, M., Trinh, I., Rissman, R. A., Konrat, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1869-0 · Cited by 28 · see citing works
Suemitsu, S., Watanabe, M., Yokobayashi, E., Usui, S., Ishikawa, T., Matsumoto, Y., Yamada, N., Okamoto, M., & Kuroda, S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.004 · Cited by 27 · see citing works
Subramanian, S., Savanur, G., & Madhavadas, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.101 · Cited by 25 · see citing works
Alzheimer's therapy development: A few points to consider
Sigurdsson, E. M. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.001 · Cited by 25 · see citing works
Self-citationNeuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models
Krishnaswamy, S., Huang, H.-W., Marchal, I. S., Ryoo, H. D., & Sigurdsson, E. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104770 · Cited by 23 · see citing works
Self-citationCzerkowicz, J., Chen, W., Wang, Q. L., Shen, C., Wager, C. G., Stone, I., Stebbins, C., Lamb, M., Setser, J. J., Cantone, G., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.1903 · Cited by 22 · see citing works
Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau
Li, D., Wang, L., Maziuk, B. F., Yao, X., Wolozin, B. L., & Cho, Y. K. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003557 · Cited by 20 · see citing works
From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers
Hales, C. M., & Hu, W. T. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.776522 · Cited by 15 · see citing works
Kerchner, G. A., Ayalon, G., Brunstein, F., Chandra, P., Datwani, A., Fuji, R. N., Manser, P. T., Vaze, A., Ward, M. R., Wildsmith, K. R., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.243 · Cited by 12 · see citing works
Chukwu, J. E., Congdon, E. E., Sigurdsson, E. M., & Kong, X. (2019) · mAbs · doi:10.1080/19420862.2019.1574530 · Cited by 12 · see citing works
Self-citationSafety and Tolerability of PNT001 in Healthy Adults
(2019) · Case Medical Research · doi:10.31525/ct1-nct04096287 · Cited by 2 · see citing works
Wu, Q., Lin, Y., Gu, J., & Sigurdsson, E. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.045 · Cited by 1 · see citing works
Self-citationStudy With Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease
(2019) · Case Medical Research · doi:10.31525/ct1-nct04149860 · Cited by 1 · see citing works
Flagged first, then by citations
1 of the 144 references couldn’t be matched to a known paper.
Research works printed but not linked: 6
- Alam R,, 2017 Preclinical characterization of an antibody [Ly3303560] targeting aggregated tau. Alzheimer’s Dementia 13 (7), P592– P593.
- Alzforum.org, 2020 Active tau vaccine: hints of slowing neurodegeneration http://www.alzforum.org/news/conference-coverage/active-tau-vaccine-hints-slowing-neurodegeneration.
- Holth JK,, 2019b The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363, 880– 884. 30679382 PMC6410369
- Marchal IS,, 2019 Neuronally expressed anti-tau scFvs and sdAbs prevent tauo-pathy-induced phenotypes in Drosophila models. Soc. Neurosci. Abstr 446, 12. PMC7178494 31982516
- Sandusky-Beltran LA,, 2019 Examining the impact of single domain anti-tau immunotherapies in an animal model of tauopathy. In: Alzheimer’s Disease & Parkinson’s Disease (ADPD) Conference Abstract Symposium 14: Treatment of Tauopathies.
- Sigurdsson EM,, 2016 Comment on “antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement” https://www.alzforum.org/papers/antibody-mediated-targeting-tau-vivo-does-not-require-effector-function-and-microglial. 27475227
Cited by
Sorted by citations
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547 · see citing works
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371 · see citing works
Mummery, C. J., Börjesson-Hanson, A., Blackburn, D. J., Vijverberg, E. G. B., De Deyn, P. P., Ducharme, S., Jonsson, M., Schneider, A., Rinne, J. O., Ludolph, A. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02326-3 · Cited by 347 · see citing works
Sengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 303 · see citing works
Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218 · see citing works
Limorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 162 · see citing works
Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study
Florian, H., Wang, D., Arnold, S. E., Boada, M., Guo, Q., Jin, Z., Zheng, H., Fisseha, N., Kalluri, H. V., Rendenbach‐Mueller, B., et al. (2023) · Brain · doi:10.1093/brain/awad024 · Cited by 137 · see citing works
New Insights Into Drug Discovery Targeting Tau Protein
Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 133 · see citing works
Current Status of Clinical Trials on Tau Immunotherapies
Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96 · see citing works
Self-citationTauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 87 · see citing works
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61 · see citing works
Singh, A., Allen, D., Fracassi, A., Tumurbaatar, B., Natarajan, C., Scaduto, P., Woltjer, R., Kayed, R., Limon, A., Krishnan, B., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200716 · Cited by 56 · see citing works
Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease
Mantile, F., & Prisco, A. (2020) · Biology · doi:10.3390/biology9120425 · Cited by 56 · see citing works
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works
“Passive immunization with monoclonal antibodies and active immunization techniques that encourage the body’s immune system to generate its own antibodies against tau are two examples of different immunotherapeutic treatments [96,97].”
BackgroundSilva, M. C., Nandi, G., Donovan, K. A., Cai, Q., Berry, B. C., Nowak, R. P., Fischer, E. S., Gray, N. S., Ferguson, F. M., & Haggarty, S. J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.801179 · Cited by 50 · see citing works
Congdon, E. E., Jiang, Y., & Sigurdsson, E. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.12.002 · Cited by 37 · see citing works
Self-citationLorenzo, D. D. (2024) · ChemMedChem · doi:10.1002/cmdc.202400180 · Cited by 40 · see citing works
Tau protein aggregation: Key features to improve drug discovery screening
Giovannini, J., Smeralda, W., Jouanne, M., Santos, J. S. O., Catto, M., & Voisin‐Chiret, A. S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.009 · Cited by 33 · see citing works
Congdon, E. E., Pan, R., Jiang, Y., Sandusky‐Beltran, L. A., Dodge, A., Lin, Y., Liu, M., Kuo, M., Kong, X., & Sigurdsson, E. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104249 · Cited by 32 · see citing works
Self-citationShen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025) · Cells · doi:10.3390/cells14191506 · Cited by 32 · see citing works
Duquette, A., Pernègre, C., Carpentier, A. V., & Leclerc, N. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.607680 · Cited by 29 · see citing works
Bhopatkar, A. A., & Kayed, R. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105122 · Cited by 27 · see citing works
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30 · see citing works
Devi, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1213968 · Cited by 29 · see citing works
Sigurdsson, E. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231238 · Cited by 27 · see citing works
Self-citationThe Structure Biology of Tau and Clue for Aggregation Inhibitor Design
Wang, D., Huang, X., Yan, L., Zhou, L., Chang, Y., Wu, J., Su, Z., & Huang, Y. (2021) · The Protein Journal · doi:10.1007/s10930-021-10017-6 · Cited by 26 · see citing works
Tau Protein-Targeted Therapies in Alzheimer’s Disease: Current State and Future Perspectives
Pluta, R. M., & Ułamek-Kozioł, M. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch4 · Cited by 24 · see citing works
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 25 · see citing works
Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma
Hedna, R., Kovacic, H., Pagano, A., Peyrot, V., Robin, M., Devred, F., & Breuzard, G. (2022) · Cancers · doi:10.3390/cancers14215386 · Cited by 24 · see citing works
Alrouji, M., Alshammari, M. S., Syed, T., & Shamsi, A. (2025) · Antioxidants · doi:10.3390/antiox14070774 · Cited by 21 · see citing works
Protein modification in neurodegenerative diseases
Ramazi, S., Dadzadi, M., Darvazi, M., Seddigh, N., & Allahverdi, A. (2024) · MedComm · doi:10.1002/mco2.674 · Cited by 24 · see citing works
Su, J., Xiao, Y., Wang, X., Zheng, J., & Wang, J. (2024) · Medicine Plus · doi:10.1016/j.medp.2024.100060 · Cited by 21 · see citing works
Immunotherapy: An emerging treatment option for neurodegenerative diseases
Mukherjee, A., Biswas, S., & Roy, I. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103974 · Cited by 21 · see citing works
Kim, C., Hovakimyan, A., Zagorski, K., Antonyan, T., Petrushina, I., Davtyan, H., Chailyan, G., Hasselmann, J., Iba, M., Adame, A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-021-00424-2 · Cited by 19 · see citing works
RetractedShamir, D. B., Deng, Y., Wu, Q., Modak, S., Congdon, E. E., & Sigurdsson, E. M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.602292 · Cited by 18 · see citing works
Self-citationHelboe, L., Rosenqvist, N., Volbracht, C., Pedersen, L. Ø., Pedersen, J. T., Christensen, S., Egebjerg, J., Christoffersen, C. T., Bang‐Andersen, B., Beach, T. G., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220125 · Cited by 20 · see citing works
Shiravandi, A., Yari, F., Tofigh, N., Ashtiani, M. K., Shahpasand, K., Ghanian, M. H., Shekari, F., & Faridbod, F. (2022) · Biosensors · doi:10.3390/bios12100879 · Cited by 18 · see citing works
Zhang, T., Tian, Y., Zheng, X., Li, R., Hu, L., Shui, X., Mei, Y., Wang, Q., Zhang, M., Zheng, X., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14432 · Cited by 18 · see citing works
New insights into the therapeutic approaches for the treatment of tauopathies
Singh, H., Das, A., Khan, M. M., & Pourmotabbed, T. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385288 · Cited by 18 · see citing works
Fang, L., Jiao, B., Liu, X., Wang, Z., Yuan, P., Zhou, H., Xiao, X., Cao, L., Guo, J., Tang, B., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.11.018 · Cited by 17 · see citing works
Personalised regional modelling predicts tau progression in the human brain
Chaggar, P., Vogel, J. W., Binette, A. P., Thompson, T., Strandberg, O. T., Mattsson, N., Karlsson, L., Stomrud, E., Jbabdi, S., Magon, S., et al. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003241 · Cited by 17 · see citing works
Reich, N., Allsop, D., Parkin, E. T., & Dawson, N. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18477 · Cited by 14 · see citing works
Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration
Giunta, M., Solje, E., Gardoni, F., Borroni, B., & Benussi, A. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s262352 · Cited by 14 · see citing works
Phosphorylated TAR DNA-binding protein-43: Aggregation and antibody-based inhibition
Esposto, J., & Martić, S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166234 · Cited by 12 · see citing works
Role of Tau protein in long COVID and potential therapeutic targets
Marwaha, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1280600 · Cited by 11 · see citing works
Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer’s Disease
Pradhan, L. K., Sahoo, P. K., Chauhan, S., & Das, S. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02009-7 · Cited by 9 · see citing works
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s Disease
Li, H., Shen, X., Zhang, B., & Zhu, Z. (2025) · Molecules · doi:10.3390/molecules30173479 · Cited by 10 · see citing works
Sexton, C. E., Anstey, K. J., Baldacci, F., Barnum, C. J., Barron, A. M., Blennow, K., Brodaty, H., Burnham, S. C., Elahi, F. M., Götz, J., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12380 · Cited by 11 · see citing works
Self-citationTargeting tau in Alzheimer’s Disease: rationale, approach and challenges
Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10 · see citing works
Kujovic, M., Lipka, T., Zalman, M., Baumann, L., Jänner, M., & Baumann, B. (2023) · Scientific Reports · doi:10.1038/s41598-023-33701-2 · Cited by 10 · see citing works
Savonenko, A. V., Wong, P. C., & Li, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00022-8 · Cited by 8 · see citing works
Focusing on oligomeric tau as a therapeutic target in Alzheimer’s disease and other tauopathies
Rayman, J. B. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2206561 · Cited by 9 · see citing works
Bryan, M. R., Tian, X., Tseng, J., Evangelista, B., Ragusa, J. V., Bryan, A. F., Trotman, W., Irwin, D. J., & Cohen, T. J. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01865-1 · Cited by 8 · see citing works
Martín‐Ávila, A., Modak, S., Rajamohamedsait, H. B., Dodge, A., Shamir, D. B., Krishnaswamy, S., Sandusky‐Beltran, L. A., Walker, M., Lin, Y., Congdon, E. E., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116291 · Cited by 7 · see citing works
Self-citationHu, N., Ondrejčák, T., Klyubin, I. V., Yang, Y., Walsh, D. M., Livesey, F. J., & Rowan, M. J. (2024) · Brain Communications · doi:10.1093/braincomms/fcae333 · Cited by 7 · see citing works
Electrophysiological insights into Alzheimer's disease: A review of human and animal studies
Calvin, K., McNeela, A. M., Osse, A. M. L., Bhasin, G., Ridenour, M., Kinney, J. W., & Hyman, J. M. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105987 · Cited by 6 · see citing works
Holghoomi, R., Rahdar, A., Kadkhoda, J., Mohammadzadeh, V., Shirzad, M., Salehi, B., Ebrahimi, M.-S., & Pandey, S. (2026) · Nano LIFE · doi:10.1142/s179398442630013x · Cited by 6 · see citing works
Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
Panwar, A., Khan, M. I., Kumar, R., Kumar, R., Rai, S. K., & Kumar, A. (2024) · Advances in Alzheimer's Disease · doi:10.4236/aad.2024.133006 · Cited by 4 · see citing works
Kemppainen, S., Huber, N., Willman, R.-M., Zamora, A., Mäkinen, P. M., Martiskainen, H., Takalo, M., Haapasalo, A., Sobrino, T., Gómez, M. A. G., et al. (2023) · Cells · doi:10.3390/cells12101422 · Cited by 5 · see citing works
Large-scale seroepidemiology uncovers nephro-urological pathologies in persons with tau autoimmunityPreprint
Magalhães, A. D., Emmenegger, M., Cecco, E. D., Carta, M. C., Frontzek, K., Chincisan, A., Guo, J., Hornemann, S., & Aguzzi, A. (2021) · medRxiv · doi:10.1101/2021.11.24.21266833 · Cited by 4 · see citing works
Bhandari, A. K., Dhami, A. S., Hemanthlumar, R. T., Mishra, N., Joslyn, B., Roy, S., Srinivasan, J., Prajapati, K. P., Kar, K., & Anand, B. G. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102879 · Cited by 3 · see citing works
Some, A., Naskar, N., Thomas, D. M., Jeengar, M. K., & Nassar, A. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04737-3 · Cited by 3 · see citing works
Wasielewska, J. M., Bajracharya, R., Johnston, R. L., Chaves, J. C. S., Pébay, A., Oikari, L. E., Götz, J., Nisbet, R. M., & White, A. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.24.563706 · Cited by 2 · see citing works
Tau pathology in epilepsy: emerging mechanisms and translational opportunities
Sen, A., Tai, X. Y., Galanopoulou, A. S., Thom, M., Aronica, E., Vivash, L. E., Hardmeier, M., Amos, A., Rüegg, S. J., Koepp, M. J., et al. (2026) · Brain · doi:10.1093/brain/awag108 · Cited by 2 · see citing works
RNA-based therapeutics for Alzheimer’s disease and related tauopathies: challenges and opportunities
Rajbanshi, B., Brentari, I., Denti, M. A., Cummings, J. L., & Guruacharya, A. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100585 · Cited by 2 · see citing works
Targeting Endogenous Tau in Seeded Tauopathy Models Inhibits Tau Spread
Jang, E., Hoxha, K., Mozier, D., Insana, A., Farber, E., Changolkar, L. N., Zhang, B., Chio, T. I., Crowe, A., Chen, R. J., et al. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.0877-24.2024 · Cited by 2 · see citing works
Antibody-mediated clearance of an ER-resident aggregate that causes glaucoma
Thu, M., Qerqez, A. N., Hill, K. R., Azouz, L. R., Youngblood, H. A., Hill, S. E., Ku, Y., Peters, D. M. P., Maynard, J. A., & Lieberman, R. L. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae556 · Cited by 3 · see citing works
Therapeutic Modalities Targeting Tau Protein in Alzheimer’s Disease
Schreiner, T. G., Iacob, L., Vasilache, C., & Schreiner, O. D. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2030032 · Cited by 2 · see citing works
Pazili, T. H. (2024) · Case Reports in Neurological Medicine · doi:10.1155/2024/8353492 · Cited by 1 · see citing works
RetractedInvestigating Neurodegenerative Diseases From Alzheimer's to Parkinson's
Khare, N., Khare, P., & Priyadarshi, S. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-5464-3.ch015 · Cited by 1 · see citing works
Dai, C.-L., Song, Y., Chen, Y., Tung, Y. C., Huang, W., Gong, C., & Lovell, J. F. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101167 · Cited by 1 · see citing works
Nabi, S. U., Rasool, I., Khan, A., Haq, A. U., Hussain, I., Khan, M. S., Majid, S., Rashid, S., Rashid, S. M., Sehar, N., et al. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-025-01781-w · Cited by 1 · see citing works
Guedjdal, S., Leghay, C., Derisbourg, M. J., Eddarkaoui, S., Lecerf, S., Vermon, F., Caillierez, R., Bégard, S., Regost, C., Laloux, C., et al. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00550-8 · Cited by 2 · see citing works
Belavadi, S., & Kadiri, S. K. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178913 · Cited by 1 · see citing works
Advances in the treatment of Alzheimer’s disease
Goceroglu, R. T., & Hacımüftüoğlu, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819165 · Cited by 1 · see citing works
Silva, M. C., Lindmeier, H., Pigini, P., Laughlin, J., Yu, Y., Morrill, C., Arnold, M. A., Barraza, S. J., Saadipour, K., Dieterich, M., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady6759 · Cited by 2 · see citing works
Pathophysiology and Management Approaches in Alzheimer’s Disease
Jain, S., Goel, D., Nazir, S. S., Yadav, V., & Vohora, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_4 · Cited by 1 · see citing works
The evolution of Alzheimer’s disease therapies: A comprehensive review
Paul, P., Bhattacharjee, A., Bordoloi, S. K., & Paul, U. K. (2024) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_37_23 · Cited by 1 · see citing works
Terapéutica con anticuerpos monoclonales en la enfermedad de Alzheimer
Maliza-Moposita, J. A., & Salazar-Garcés, L. F. (2024) · MQRInvestigar · doi:10.56048/mqr20225.8.3.2024.2739-2760 · Cited by 1 · see citing works
MAPT Splicing Modulators as a Therapeutic Strategy for TauopathiesPreprint
Silva, M. C., Lindmeier, H., Pigini, P., Laughlin, J., Yu, Y., Morrill, C., Arnold, M. A., Barraza, S. J., Saadipour, K., Dieterich, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.06.652428 · Cited by 1 · see citing works
Noninfectious Disease Vaccines
Speiser, D. E., El-Turabi, A., & Bachmann, M. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00042-6
Mortelecque, J., Danis, C., Landrieu, I., & Dupré, E. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3629-9_8
The interplay between tauopathies and neurodegeneration
Milik, B. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00012-9
APOE Polymorphism and Brain Imaging
Obenaus, A., & Territo, P. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_69-1
Chaggar, P., Vogel, J. W., Thompson, T., Aldea, R., Strandberg, O. T., Stomrud, E., Palmqvist, S., Ossenkoppele, R., Jbabdi, S., Magon, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.27.701320
Selective disruption of tau–SH3 interactions rescues seizure and sleep phenotypes
Shandilya, M., Koutures, A., Addo-Osafo, K., Hwang, K., Vicente, M. C., Ewens, A. N., Katz, B. M., Peters, S., Choquette, J. M., Vaknalli, R. N., et al. (2026) · Brain · doi:10.1093/brain/awag090
Maslii, V. P., Suprun, T. I., & Beiresh, Y. V. (2026) · Reports of Vinnytsia National Medical University · doi:10.31393/reports-vnmedical-2026-30(1)-29
Targeting amyloid and Tau: Antibody therapies for Alzheimer’s disease
Upadhyay, R., Sangitha, & Sevanan, M. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.011
- Authors
- Sandusky-Beltran, L. A., & Sigurdsson, E. M.
- Affiliations
- NYU Langone Health (US)
- Corresponding author
- Sigurdsson, E.M.
- ORCID
- Sigurdsson, E.M.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 175
- Pages
- 108104
- ISSN
- 0028-3908 (ISSN-L)
- PMC
- PMC7492435
- OpenAlex
- W3021316273
- Cited by
- 90
- References
- 144
- Citations by year
- 2026: 14 · 2025: 11 · 2024: 20 · 2023: 16 · 2022: 12 · 2021: 10 · 2020: 7
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R21 AG058282, R21 AG059391, R01 NS077239, R01 AG032611, P30 AG008051)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau immunotherapy, tau protein, Alzheimer's disease, tauopathy, humanized monoclonal antibody, antibody properties, clinical trials, disease-modifying therapy, neurodegenerative diseases, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Antibodies, Clinical Trials as Topic, Humans, Immunotherapy, tau Proteins, Tauopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
